NASDAQ:ADIL Adial Pharmaceuticals (ADIL) Stock Forecast, Price & News $2.52 -0.01 (-0.40%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$2.51▼$2.6550-Day Range$2.52▼$8.0352-Week Range$2.50▼$15.00Volume12,076 shsAverage Volume34,232 shsMarket Capitalization$3.07 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About Adial Pharmaceuticals (NASDAQ:ADIL) StockAdial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.Read More ADIL Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADIL Stock News HeadlinesSeptember 18, 2023 | americanbankingnews.comAdial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest UpdateSeptember 5, 2023 | finance.yahoo.comAdial Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceSeptember 24, 2023 | Stansberry Research (Ad)Investing Legend Warns: NVIDIA is a "Delusion"Irrational investment in this tech giant may have made it “too big to succeed” says this renowned expert. Read this before you buy shares.August 28, 2023 | finance.yahoo.comAdial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss the Need for New Alcohol Use Disorder Treatments at the European Society for Biomedical Research on AlcoholismAugust 23, 2023 | finanznachrichten.deAdial Pharmaceuticals, Inc: Adial Pharmaceuticals Regains Compliance with Nasdaq Listing RequirementsAugust 23, 2023 | finance.yahoo.comAdial Pharmaceuticals Regains Compliance with Nasdaq Listing RequirementsAugust 22, 2023 | msn.comAdial Pharmaceuticals reports Q2 resultsAugust 21, 2023 | finance.yahoo.comAdial Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business UpdateSeptember 24, 2023 | Legacy Research (Ad)Watch SHOCKING Footage of AI Facility with Ties to Elon MuskI recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.August 21, 2023 | finance.yahoo.comAdial Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business UpdateAugust 4, 2023 | finance.yahoo.comAdial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement and Reduce the Public FloatJuly 13, 2023 | marketwatch.comAdial Pharma to Conduct Two More AD04 Phase 3 Trials After Regulatory FeedbackJuly 12, 2023 | msn.comBrookline Capital Reiterates Adial Pharmaceuticals (ADIL) Buy RecommendationJuly 11, 2023 | finanznachrichten.deAdial Pharmaceuticals, Inc: Adial Provides Business Update Following Favorable Comments from US and EU Regulatory MeetingsJuly 11, 2023 | marketwatch.comAdial Pharmaceuticals Shares Nearly Double After FDA FeedbackJuly 11, 2023 | msn.comWhy Are Adial Pharmaceuticals Shares Soaring TodayJuly 11, 2023 | finance.yahoo.comAdial Provides Business Update Following Favorable Comments from US and EU Regulatory MeetingsJune 1, 2023 | finance.yahoo.comAdial Pharmaceuticals to Present at the 2023 Jefferies Global Healthcare Conference on June 9thMay 12, 2023 | finanznachrichten.deAdial Pharmaceuticals, Inc: Adial Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business UpdateMay 12, 2023 | finance.yahoo.comAdial Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business UpdateMay 12, 2023 | finance.yahoo.comAdial Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business UpdateMay 10, 2023 | finance.yahoo.comAdial Pharmaceuticals Receives Notice of Exercise from Adovate for the Acquisition of Purnovate’s Assets and BusinessApril 4, 2023 | finance.yahoo.comIs Adial Pharmaceuticals (ADIL) Stock Outpacing Its Medical Peers This Year?March 31, 2023 | finanznachrichten.deAdial Pharmaceuticals, Inc: Adial Pharmaceuticals Reports 2022 Fiscal Year Financial Results and Provides Business UpdateMarch 30, 2023 | finance.yahoo.comAdial Pharmaceuticals Reports 2022 Fiscal Year Financial Results and Provides Business UpdateMarch 30, 2023 | finance.yahoo.comAdial Pharmaceuticals Reports 2022 Fiscal Year Financial Results and Provides Business UpdateMarch 21, 2023 | finance.yahoo.comAdial Pharmaceuticals Engages The Keswick Group to Advance Partnering Activities for the Clinical Development of AD04 for Alcohol Use DisorderSee More Headlines Receive ADIL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adial Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ADIL Company Calendar Last Earnings8/21/2023Today9/24/2023Next Earnings (Estimated)11/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ADIL CUSIPN/A CIK1513525 Webwww.adialpharma.com Phone(434) 422-9800FaxN/AEmployees16Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($7.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,730,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-309.24% Return on Assets-196.48% Debt Debt-to-Equity RatioN/A Current Ratio4.43 Quick Ratio4.43 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.17 per share Price / Book0.79Miscellaneous Outstanding Shares1,220,000Free Float960,000Market Cap$3.07 million OptionableNot Optionable Beta1.03 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Cary John Claiborne MBA (Age 62)CEO, Pres & Director Comp: $415.08kMr. Joseph A. M. Truluck M.B.A. (Age 45)MBA, CFO, Treasurer & Sec. Comp: $279.7kDr. Bankole A. Johnson DSc (Age 63)FRCPsych, M.D., M.Phil, Ph.D., Founder & Chief Medical Officer Mr. John R. Martin J.D.Gen. CounselMr. Alex LugovoyChief Bus. OfficerDr. Jack W. Reich Ph.D. (Age 74)Head of Regulatory Mr. Mark H. PeikinChief Strategy Officer & Chief Devel. OfficerMr. Lawrence Goldman CPA (Age 67)Controller Ms. Catherine FratilaControllerMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFAmpio PharmaceuticalsNYSE:AMPEAridis PharmaceuticalsNASDAQ:ARDSAditxtNASDAQ:ADTXPetros PharmaceuticalsNASDAQ:PTPIView All CompetitorsInstitutional OwnershipBlackRock Inc.Sold 31,491 shares on 8/11/2023Ownership: 16.197%Simplex Trading LLCSold 1,100 shares on 8/4/2023Ownership: 0.000%View All Institutional Transactions ADIL Stock - Frequently Asked Questions Should I buy or sell Adial Pharmaceuticals stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adial Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ADIL shares. View ADIL analyst ratings or view top-rated stocks. How have ADIL shares performed in 2023? Adial Pharmaceuticals' stock was trading at $5.3750 at the start of the year. Since then, ADIL stock has decreased by 53.1% and is now trading at $2.52. View the best growth stocks for 2023 here. Are investors shorting Adial Pharmaceuticals? Adial Pharmaceuticals saw a decline in short interest in August. As of August 31st, there was short interest totaling 64,600 shares, a decline of 12.6% from the August 15th total of 73,900 shares. Based on an average daily trading volume, of 131,100 shares, the days-to-cover ratio is presently 0.5 days. Approximately 6.2% of the shares of the stock are short sold. View Adial Pharmaceuticals' Short Interest. When is Adial Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. View our ADIL earnings forecast. How were Adial Pharmaceuticals' earnings last quarter? Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) posted its earnings results on Monday, August, 21st. The company reported ($1.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.50) by $0.17. When did Adial Pharmaceuticals' stock split? Adial Pharmaceuticals's stock reverse split before market open on Monday, August 7th 2023. The 1-25 reverse split was announced on Monday, August 7th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of Adial Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Adial Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Global Partners (GLP), Corbus Pharmaceuticals (CRBP), Aytu BioPharma (AYTU), T2 Biosystems (TTOO), AIM ImmunoTech (AIM), Tandem Diabetes Care (TNDM), vTv Therapeutics (VTVT), Acasti Pharma (ACST) and Adamis Pharmaceuticals (ADMP). When did Adial Pharmaceuticals IPO? (ADIL) raised $8 million in an IPO on Friday, July 27th 2018. The company issued 1,500,000 shares at $5.00 per share. Joseph Gunnar & Co. served as the underwriter for the IPO and Dawson James Securities was co-manager. What is Adial Pharmaceuticals' stock symbol? Adial Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADIL." Who are Adial Pharmaceuticals' major shareholders? Adial Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (16.20%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Bankole A Johnson, James W Jr Newman and William B Stilley III. View institutional ownership trends. How do I buy shares of Adial Pharmaceuticals? Shares of ADIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Adial Pharmaceuticals' stock price today? One share of ADIL stock can currently be purchased for approximately $2.52. How much money does Adial Pharmaceuticals make? Adial Pharmaceuticals (NASDAQ:ADIL) has a market capitalization of $3.07 million. The company earns $-12,730,000.00 in net income (profit) each year or ($7.54) on an earnings per share basis. How can I contact Adial Pharmaceuticals? Adial Pharmaceuticals' mailing address is 1180 Seminole Trail Suite 495, Charlottesville VA, 22901. The official website for the company is www.adialpharma.com. The company can be reached via phone at (434) 422-9800 or via email at investor_relations@haynesintl.com. This page (NASDAQ:ADIL) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adial Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.